CD19 and neoplasm: We next determined whether CAR linker mAb allows for the specific detection of CAR T-cells by the simultaneous presence of bsAbs/BiTE recognizing the same tumor antigen (e.g., CD19×CD3 BiTE blinatumomab and anti-CD19 CAR T-cells) (Figure 3A–C).